Dabrafenib plus trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.

被引：0
|
作者：
Geoerger, Birgit
Bouffet, Eric
Whitlock, James A.
Moertel, Christopher L.
Hargrave, Darren R.
Aerts, Isabelle
Cohen, Kenneth J.
Kilburn, Lindsay Baker
Wright, Karen D.
Choi, Jeea
Gasal, Eduard
Russo, Mark W.
Fox, Elizabeth
机构：
[1] Univ Paris Saclay, Gustave Roussy Canc Ctr, Villejuif, France
[2] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada
[3] Univ Minnesota, Masonic Childrens Hosp, Minneapolis, MN USA
[4] UCL Great Ormond St Inst Child Hlth, London, England
[5] PSL Res Univ, Inst Curie, Oncol Ctr SIREDO, Paris, France
[6] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[7] Childrens Natl Hosp, Washington, DC USA
[8] Boston Childrens Canc & Blood Disorders Ctr, Dana Farber Canc Inst, Boston, MA USA
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10506
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
    Hargrave, Darren R.
    Bouffet, Eric
    Tabori, Uri
    Broniscer, Alberto
    Cohen, Kenneth J.
    Hansford, Jordan R.
    Geoerger, Birgit
    Hingorani, Pooja
    Dunkel, Ira J.
    Russo, Mark W.
    Tseng, Lillian
    Dasgupta, Kohinoor
    Gasal, Eduard
    Whitlock, James A.
    Kieran, Mark W.
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7303 - 7311
  • [22] Letter to editor: The efects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis
    Bin Mujtaba, Saib
    Mughal, Zaib Un Nisa
    Malik, Abdul
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [23] Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
    Dummer, Reinhard
    Long, Georgina V.
    Robert, Caroline
    Tawbi, Hussein A.
    Flaherty, Keith T.
    Ascierto, Paolo A.
    Nathan, Paul D.
    Rutkowski, Piotr
    Leonov, Oleg
    Dutriaux, Caroline
    Mandala, Mario
    Lorigan, Paul
    Ferrucci, Pier Francesco
    Grob, Jean Jacques
    Meyer, Nicolas
    Gogas, Helen
    Stroyakovskiy, Daniil
    Arance, Ana
    Brase, Jan C.
    Green, Steven
    Haas, Tomas
    Masood, Aisha
    Gasal, Eduard
    Ribas, Antoni
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1428 - +
  • [24] Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Long, Georgina V.
    Weber, Jeffrey S.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Daud, Adil
    Gonzalez, Rene
    Sosman, Jeffrey A.
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Kefford, Richard F.
    Lawrence, Donald
    Kudchadkar, Ragini
    Burris, Howard A., III
    Falchook, Gerald S.
    Algazi, Alain
    Lewis, Karl
    Puzanov, Igor
    Ibrahim, Nageatte
    Sun, Peng
    Cunningham, Elizabeth
    Kline, Amy S.
    Buono, HeatherDel
    OpattMcDowell, Diane
    Patel, Kiran
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : 871 - +
  • [25] Combination therapy of dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2021, 20 (05) : 506 - 507
  • [26] Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
    Aglietta, Massimo
    Chiarion-Sileni, Vanna
    Fava, Paolo
    Guidoboni, Massimo
    Depenni, Roberta
    Minisini, Alessandro
    Consoli, Francesca
    Ascierto, Paolo
    Rinaldi, Gaetana
    Banzi, Maria
    Marconcini, Riccardo
    Gueli, Rossana
    Ferraresi, Virginia
    Tucci, Marco
    Tonini, Giuseppe
    Lo Re, Giovanni
    Guida, Michele
    Del Vecchio, Michele
    Marcon, Ilaria Gioia
    Queirolo, Paola
    TARGETED ONCOLOGY, 2021, 16 (06) : 789 - 799
  • [27] Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
    Si, Lu
    Zhang, Xiaoshi
    Shin, Sang Joon
    Fan, Yun
    Lin, Chia-Chi
    Kim, Tae Min
    Dechaphunkul, Arunee
    Maneechavakajorn, Jedzada
    Wong, Chi Sing
    Ilankumaran, Palanichamy
    Lee, Dung-Yang
    Gasal, Eduard
    Li, Haifu
    Guo, Jun
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 31 - 38
  • [28] Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
    Long, Georgina, V
    Eroglu, Zeynep
    Infante, Jeffrey
    Patel, Sapna
    Daud, Adil
    Johnson, Douglas B.
    Gonzalez, Rene
    Kefford, Richard
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Sharfman, William
    McWilliams, Robert
    Sznol, Mario
    Redhu, Suman
    Gasal, Eduard
    Mookerjee, Bijoyesh
    Weber, Jeffrey
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 667 - +
  • [29] Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
    Massimo Aglietta
    Vanna Chiarion-Sileni
    Paolo Fava
    Massimo Guidoboni
    Roberta Depenni
    Alessandro Minisini
    Francesca Consoli
    Paolo Ascierto
    Gaetana Rinaldi
    Maria Banzi
    Riccardo Marconcini
    Rossana Gueli
    Virginia Ferraresi
    Marco Tucci
    Giuseppe Tonini
    Giovanni Lo Re
    Michele Guida
    Michele Del Vecchio
    Ilaria Gioia Marcon
    Paola Queirolo
    Targeted Oncology, 2021, 16 : 789 - 799
  • [30] Resolution of Ascites Following Targeted Therapy in a Pediatric Patient With BRAF V600E-Mutant Low-Grade Glioma
    Crentsil, Hannah E.
    Felker, James
    PEDIATRIC BLOOD & CANCER, 2025, 72 (03)
12345